Internal CFO promotion signals management stability and continuity. Monitor for any strategic shifts under the new CFO, but no immediate catalyst. The outgoing CFO's departure is amicable with a transition period through end of November.
Price Chart
Executive Summary
CRISPR Therapeutics announced the promotion of Andrew J. Silver from SVP, Finance to CFO, effective October 19, 2026, replacing Raju Prasad who resigned to pursue external opportunities. The filing is a routine executive succession with an internal promotion, no red flags in the departure, and standard compensation terms.
Key Facts
- Andrew J. Silver appointed CFO effective October 19, 2026, promoted from SVP, Finance (role held since January 2025).
- Outgoing CFO Raju Prasad resigned to pursue external opportunities; no disagreement with the company cited; expected to remain employed through November 30, 2026.
- Silver receives annual base salary of $515,000, target bonus of 45% of base salary, and a one-time RSU grant of 25,000 shares vesting fully on the second anniversary.
- Employment agreement includes 6-month notice period for involuntary termination (12 months within 12 months of a Change in Control), with continued vesting and pro-rated bonus during notice period.
Financial Impact
No material financial impact; CFO compensation is standard for a mid-cap biotech.
Risk Factors
- Loss of institutional knowledge if outgoing CFO departs before transition complete.
- No material risks identified from this routine executive change.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-425243 |
| Document: crsp-20261019.htm | 0001193125-26-425243 |
| Document: 0001193125-26-425243-index-headers.html | 0001193125-26-425243 |
| Document: 0001193125-26-425243-index.html | 0001193125-26-425243 |
| Document: 0001193125-26-425243.txt | 0001193125-26-425243 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | Insider Cluster | $50.50 | awaiting T+20 | — | $49.39 (+2.20%) |
Oct 19, 2026 7d ago | 8-K | $49.88 | awaiting T+20 | — | $49.39 (−0.98%) |
Oct 16, 2026 10d ago | Insider Cluster | $50.04 | awaiting T+20 | — | $49.39 (−1.30%) |
Oct 16, 2026 10d ago | Insider Cluster | $50.04 | awaiting T+20 | — | $49.39 (+1.30%) |
Oct 15, 2026 11d ago | Insider Cluster | $49.25 | awaiting T+20 | — | $49.39 (+0.28%) |
Oct 14, 2026 12d ago | 144 | $51.52 | awaiting T+20 | — | $49.39 (−4.13%) |
Oct 6, 2026 20d ago | 144 | $52.35 | awaiting T+20 | — | $49.39 (−5.65%) |
Sep 24, 2026 4w ago | Insider Cluster | $54.23 $49.39 | ▲ +8.92% | ▲ +7.45% | $49.39 (+8.92%) |
Aug 28, 2026 8w ago | Press Release | $57.72 $54.23 | ▼ −6.05% | ▼ −6.56% | $49.39 (−14.43%) |
Aug 3, 2026 12w ago | Press Release | $53.07 $56.82 | ▲ +7.07% | ▲ +8.30% | $49.39 (−6.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers